GLP-1 receptor agonists have been effectively used in clinical trials for the treatment of T2DM, and various GLP-1-based pharmacotherapies are now being evaluated in clinical trials for the treatment of obesity [19]. This evidence concerns the gene GCG and obesity disorder.